

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

EQA round: E21/19 - Hormones 2

Dead line: 12.02.2019

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability						
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}
(193) Ferritin					9						9	9	100%
Samples and groups	[µg/L]												
Sample A		104	7,9	7,6	9						9	9	100%
Other					9						9		
								1x 4/1, 3x 4/60, 3x 4/179, 1x 6/58, 1x 6/60					
Sample B		95,9	6,0	6,3	9						9	9	100%
Other					9						9		
								1x 4/1, 3x 4/60, 3x 4/179, 1x 6/58, 1x 6/60					
(320) LH					8						8	8	100%
Samples and groups	[U/L]												
Sample A		79,2	13	17	8						8	8	100%
Other					8						8		
								2x 4/1, 2x 4/12, 4x 4/60					
Sample B		28,7	9,4	33	8						8	8	100%
Other					8						8		
								2x 4/1, 2x 4/12, 4x 4/60					
(321) FSH					8						8	8	100%
Samples and groups	[U/L]												
Sample A		5,23	0,41	7,8	8						8	8	100%
Other					8						8		
								2x 4/1, 2x 4/12, 4x 4/60					
Sample B		26,4	1,4	5,3	8						8	8	100%
Other					8						8		
								2x 4/1, 2x 4/12, 4x 4/60					
(322) Prolactin					8						8	8	100%
Samples and groups	[mU/L]												
Sample A		555	65	12	8						8	8	100%
Other					8						8		
								2x 4/1, 1x 4/12, 3x 4/60, 2x 4/179					
Sample B		545	65	12	8						8	8	100%
Other					8						8		
								2x 4/1, 1x 4/12, 3x 4/60, 2x 4/179					
(325) Insulin					5						5	5	100%
Samples and groups	[mU/L]												
Sample A		38,7	8,6	22	5						5	5	100%
Other					5						5		
								1x 4/1, 1x 4/12, 1x 4/60, 2x 4/179					
Sample B		76,8	17	22	5						5	5	100%
Other					5						5		
								1x 4/1, 1x 4/12, 1x 4/60, 2x 4/179					
(326) Folate					10						10	9	90%
Samples and groups	[nmol/L]												
Sample A		13,6	3,5	25	10						10	10	100%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		11,4	0,73	6,4	5	0	CVPG	10,9	0,20	27%	7,95	13,9	5
Other					5	0					5		
								2x 4/1, 1x 4/12, 2x 4/179					
Sample B		4,97	0,80	16	10						10	9	90%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		4,84	0,45	9,4	5	0	CVPG	4,8	0,11	±1,35	3,45	6,15	5
Other					5	0					5		
								2x 4/1, 1x 4/12, 2x 4/179					
(327) Vitamin B12					10						10	10	100%
Samples and groups	[pmol/L]												
Sample A		530	45	8,5	10						10	10	100%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		543	26	4,8	5	0	CVPG	545	3,5	20%	436	654	5
Other					5	0					5		
								2x 4/1, 1x 4/12, 2x 4/179					
Sample B		236	27	11	10						10	10	100%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		251	24	9,6	5	0	CVPG	254	2,2	20%	203	305	5
Other					5	0					5		
								2x 4/1, 1x 4/12, 2x 4/179					
(328) hGH					2						2	2	100%
Samples and groups	[mU/L]												
Sample A		17,5	0,055	0,31	2						2	2	100%
Other					2	0					2		
								2x 4/29					
Sample B		34,1	2,0	5,7	2						2	2	100%

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

EQA round: E21/19 - Hormones 2

Dead line: 12.02.2019

Test	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability							
							AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(328) hGH					2							2	2	100%
Samples and groups	[mU/L]													
Sample B		34,1	2,0	5,7	2							2	2	100%
Other					2	0						2		
						2x 4/29								
(329) IGF-1					3							3	3	100%
Samples and groups	[µg/L]													
Sample A		520	120	23	3							3	3	100%
Other					3	0						3		
						2x 4/29, 1x 4/60								
Sample B		158	10	6,6	3							3	3	100%
Other					3	0						3		
						2x 4/29, 1x 4/60								
(390) Renin					2							2	2	100%
Samples and groups	[ng/L]													
Sample A		35,9	1,4	3,8	2							2	2	100%
Other					2	0						2		
						2x 4/164								
Sample B		39,3	0,33	0,84	2							2	2	100%
Other					2	0						2		
						2x 4/164								
(393) C-peptide					7							7	7	100%
Samples and groups	[pmol/L]													
Sample A		271	86	32	7							7	7	100%
Other					7	0						7		
						2x 4/1, 3x 4/60, 2x 4/179								
Sample B		325	100	31	7							7	7	100%
Other					7	0						7		
						2x 4/1, 3x 4/60, 2x 4/179								
(394) SHBG					5							5	5	100%
Samples and groups	[nmol/L]													
Sample A		32,4	2,6	8,0	5							5	5	100%
Other					5	0						5		
						1x 4/1, 4x 4/60								
Sample B		122	17	14	5							5	5	100%
Other					5	0						5		
						1x 4/1, 4x 4/60								
(405) Parathyroid hormone (PTH)					8							8	8	100%
Samples and groups	[pmol/L]													
Sample A		16,5	1,9	12	8							8	8	100%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		16,2	1,5	9,5	6	0	CVPG	15,8	0,18	23%	12,1	19,5	6	
Other					2	0						2		
						1x 4/1, 1x 4/12								
Sample B		1,01	0,25	25	8							8	8	100%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		1,02	0,24	23	6	0	CVPG	1,03	0,018	±0,28	0,754	1,31	6	
Other					2	0						2		
						1x 4/1, 1x 4/12								

st_kn_p

End of report

Printed: 03.03.2019